Kymera Therapeutics (KYMR) Misses Q4 EPS by 11c
Tweet
Share
E-mailGet Alerts KYMR Hot Sheet
Join SI Premium – FREE
Kymera Therapeutics (NASDAQ: KYMR) reported Q4 EPS of ($0.88), $0.11 worse than the analyst estimate of ($0.77). Revenue for the quarter came in at $7.39 million versus the consensus estimate of $14.71 million.
For earnings history and earnings-related data on Kymera Therapeutics (KYMR) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Kymera Therapeutics (KYMR) PT Raised to $170 at Guggenheim
- RBC Capital Starts Mettler-Toledo (MTD) at Sector Perform
- Berenberg Reiterates Buy Rating on Tharisa Plc (THS:LN)
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
